# Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

> **NCT04701333** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 73 (actual)

## Conditions studied

- Lactation Suppressed

## Interventions

- **DRUG:** Cabergoline 1 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04701333
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2022-06-24
- **Final completion:** 2023-03-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701333, "Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04701333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*